Adial Pharmaceuticals, Inc.ADILNASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank58
5Y CAGR-33.1%
Year-over-Year Change
Year-over-year SG&A expense growth
5Y CAGR
-33.1%/yr
Long-term compound
Percentile
P58
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q3 2025 | 8.04% |
| Q2 2025 | -24.34% |
| Q1 2025 | 25.67% |
| Q4 2024 | 2.54% |
| Q3 2024 | -7.43% |
| Q2 2024 | -8.35% |
| Q1 2024 | -8.46% |
| Q4 2023 | 32.02% |
| Q3 2023 | 9.86% |
| Q2 2023 | -44.96% |
| Q1 2023 | -7.87% |
| Q4 2022 | 11.14% |
| Q3 2022 | -27.51% |
| Q2 2022 | 4.11% |
| Q1 2022 | 19.93% |
| Q4 2021 | -13.42% |
| Q3 2021 | 13.77% |
| Q2 2021 | -25.25% |
| Q1 2021 | 98.19% |
| Q4 2020 | -5.64% |
| Q3 2020 | 60.21% |
| Q2 2020 | -24.98% |
| Q1 2020 | 39.88% |
| Q4 2019 | 0.62% |
| Q3 2019 | -7.08% |
| Q2 2019 | -39.29% |
| Q1 2019 | 49.86% |
| Q4 2018 | -71.26% |
| Q3 2018 | 117.93% |
| Q2 2018 | 486.11% |
| Q1 2018 | 5.26% |
| Q4 2017 | 15.00% |
| Q3 2017 | 27.77% |
| Q2 2017 | 46.75% |
| Q1 2017 | 109.56% |
| Q4 2016 | -1.83% |
| Q3 2016 | 5.71% |
| Q2 2016 | -33.57% |
| Q1 2016 | 0.00% |